FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

0 مناظر· 09/21/23
OncLive® On Air
OncLive® On Air
0 سبسکرائبرز
0
میں

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.

مزید دکھائیں

 0 تبصرے sort   ترتیب دیں


اگلا